Show simple item record

dc.contributor.authorZheng, Qianen_US
dc.contributor.authorWang, Zhaohuien_US
dc.contributor.authorZhang, Huipingen_US
dc.contributor.authorHuang, Qien_US
dc.contributor.authorMadsen, Joren C.en_US
dc.contributor.authorSachs, David H.en_US
dc.contributor.authorHuang, Christene A.en_US
dc.contributor.authorWang, Zhiruien_US
dc.date.accessioned2017-11-21T20:43:24Z
dc.date.issued2017en_US
dc.identifier.citationZheng, Qian, Zhaohui Wang, Huiping Zhang, Qi Huang, Joren C. Madsen, David H. Sachs, Christene A. Huang, and Zhirui Wang. 2017. “Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumors.” Molecular Oncology 11 (5): 584-594. doi:10.1002/1878-0261.12056. http://dx.doi.org/10.1002/1878-0261.12056.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34375188
dc.description.abstractCD19 is expressed on normal and neoplastic B cells and is a promising target for immunotherapy. However, there is still an unmet need to further develop novel therapeutic drugs for the treatment of the refractory/relapsing human CD19+ tumors. We have developed a diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumors. We have constructed three isoforms of the CD19 immunotoxin: monovalent, bivalent, and foldback diabody. In vitro binding affinity and efficacy analysis demonstrated that the bivalent isoform had the highest binding affinity and in vitro efficacy. The in vivo efficacy of the CD19 immunotoxins was assessed using human CD19+ JeKo‐1 tumor‐bearing NOD/SCID IL‐2 receptor γ−/− (NSG) mouse model. In these animals, CD19 immunotoxins significantly prolonged the median survival from 31 days in controls to 34, 36, and 40 days in animals receiving the monovalent isoform, foldback diabody isoform, and bivalent isoform, respectively. The bivalent CD19 immunotoxin is a promising therapeutic drug candidate for targeting relapsing/refractory human CD19+ tumors.en
dc.language.isoen_USen
dc.publisherJohn Wiley and Sons Inc.en
dc.relation.isversionofdoi:10.1002/1878-0261.12056en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527461/pdf/en
dash.licenseLAAen_US
dc.subjectdiphtheria toxinen
dc.subjecthumanen
dc.subjectimmunotoxinen
dc.subjecten
dc.titleDiphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumorsen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalMolecular Oncologyen
dash.depositing.authorMadsen, Joren C.en_US
dc.date.available2017-11-21T20:43:24Z
dc.identifier.doi10.1002/1878-0261.12056*
dash.authorsorderedfalse
dash.contributor.affiliatedMadsen, Joren
dash.contributor.affiliatedWang, Zhirui
dash.contributor.affiliatedHuang, Christene
dash.contributor.affiliatedSachs, David


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record